Open AccessMonitoring HSP70 exosomes in cancer patients’ follow up: a clinical prospective pilot study
Author(s) -
Chanteloup Gaëtan,
Cordonnier Marine,
Isambert Nicolas,
Bertaut Aurélie,
Hervieu Alice,
Hennequin Audrey,
Luu Maxime,
Zanetta Sylvie,
Coudert Bruno,
Bengrine Leila,
Desmoulins Isabelle,
Favier Laure,
Lagrange Aurélie,
Pages PierreBenoit,
Gutierrez Ivan,
Lherminier Jeanine,
Avoscan Laure,
Jankowski Clémentine,
Rébé Cédric,
Chevriaux Angélique,
Padeano MarieMartine,
Coutant Charles,
Ladoire Sylvain,
Causeret Sylvain,
Arnould Laurent,
CharonBarra Céline,
Cottet Vanessa,
Blanc Julie,
Binquet Christine,
Bardou Marc,
Garrido Carmen,
Gobbo Jessica
Publication year - 2020
Publication title -
journal of extracellular vesicles
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.94
H-Index - 68
ISSN - 2001-3078
DOI - 10.1080/20013078.2020.1766192
Subject(s) - microvesicles , exosome , hsp70 , medicine , cancer , cancer research , prospective cohort study , cancer cell , disease , metastasis , oncology , immunology , heat shock protein , biology , microrna , gene , biochemistry
Exosomes are nanovesicles released by all cells that can be found in the blood. A key point for their use as potential biomarkers in cancer is to differentiate tumour‐derived exosomes from other circulating nanovesicles. Heat shock protein‐70 (HSP70) has been shown to be abundantly expressed by cancer cells and to be associated with bad prognosis. We previously showed that exosomes derived from cancer cells carried HSP70 in the membrane while those from non‐cancerous cells did not. In this work, we opened a prospective clinical pilot study including breast and lung cancer patients to determine whether it was possible to detect and quantify HSP70 exosomes in the blood of patients with solid cancers. We found that circulating exosomal HSP70 levels, but not soluble HSP70, reflected HSP70 content within the tumour biopsies. Circulating HSP70 exosomes increased in metastatic patients compared to non‐metastatic patients or healthy volunteers. Further, we demonstrated that HSP70‐exosome levels correlated with the disease status and, when compared with circulating tumour cells, were more sensitive tumour dissemination predictors. Finally, our case studies indicated that HSP70‐exosome levels inversely correlated with response to the therapy and that, therefore, monitoring changes in circulating exosomal HSP70 might be useful to predict tumour response and clinical outcome.